Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations - PubMed (original) (raw)
Review
Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations
M Lazzaroni et al. Aliment Pharmacol Ther. 2004 Jul.
Free article
Abstract
Although adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs) occur in only a small proportion of users, the widespread use of these drugs has resulted in a substantial overall number of affected persons who experience serious gastrointestinal complications. Dyspeptic symptoms are estimated to occur in 10-60% of NSAID users and lead to discontinuation of treatment in 5-15% of rheumatoid arthritis patients taking NSAIDs. It is now well established that the point prevalence of peptic ulcer disease in patients receiving conventional NSAID therapy ranges between 10 and 30%, representing a 10-30-fold increase over that found in the general population. One of 175 users of conventional NSAIDs in the USA will be hospitalized each year for NSAID-induced gastrointestinal damage. The mortality of hospitalized patients remains about 5-10%, with an expected annual death rate of 0.08%. The selective COX-II inhibitors (rofecoxib, celecoxib, parecoxib, etoricoxib, valdecoxib, lumiracoxib) show consistently comparable efficacy to that of conventional non-steroidal anti-inflammatory drugs (NSAIDs) in patients with rheumatoid arthritis and osteoarthritis, but have a significantly reduced propensity to cause gastrointestinal toxicity. In many cases, the gastric effects of therapeutically active doses of COX-II inhibitors are indistinguishable from placebo. The safety benefits of COX-2 inhibitors given alone appear similar to combined therapy with conventional NSAIDs and gastroprotective agents. These findings warrant the consideration of COX-II inhibitors as first-line therapy in patients requiring long-term pain control.
Similar articles
- COXIBs and non-selective NSAIDs in the gastroenterological setting: what should patients and physicians do?
Lazzaroni M, Battocchia A, Bianchi Porro G. Lazzaroni M, et al. Dig Liver Dis. 2007 Jun;39(6):589-96. doi: 10.1016/j.dld.2007.04.002. Epub 2007 Apr 24. Dig Liver Dis. 2007. PMID: 17459794 - Clinical experience with cyclooxygenase-2 inhibitors.
Lanas A. Lanas A. Rheumatology (Oxford). 2002 Apr;41 Supp 1:16-22; discussion 35-42. Rheumatology (Oxford). 2002. PMID: 12173276 Review. - A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN, Callaghan R, Allen ME, Rowe IF. Price-Forbes AN, et al. Rheumatology (Oxford). 2005 Jul;44(7):921-4. doi: 10.1093/rheumatology/keh642. Epub 2005 Apr 12. Rheumatology (Oxford). 2005. PMID: 15827035 - [The lack of awareness of the Israeli population regarding gastrointestinal complications from non-steroidal anti-inflammatory drugs].
Zandman-Goddard G, Langevitz P. Zandman-Goddard G, et al. Harefuah. 2001 Jun;140(6):476-8, 567, 566. Harefuah. 2001. PMID: 11420844 Hebrew. - Clinical pharmacology of selective COX-2 inhibitors.
Capone ML, Tacconelli S, Sciulli MG, Patrignani P. Capone ML, et al. Int J Immunopathol Pharmacol. 2003 May-Aug;16(2 Suppl):49-58. Int J Immunopathol Pharmacol. 2003. PMID: 14552704 Review.
Cited by
- Gastroprotective Effect of 2,3-Dimethylquinoxaline Against Indomethacin-Induced Gastric Ulcer in Rat.
Alfadil A. Alfadil A. J Inflamm Res. 2024 Mar 29;17:1983-1994. doi: 10.2147/JIR.S453425. eCollection 2024. J Inflamm Res. 2024. PMID: 38566982 Free PMC article. - Systematic Review on Herbal Preparations for Controlling Visceral Hypersensitivity in Functional Gastrointestinal Disorders.
Lashgari NA, Roudsari NM, Momtaz S, Niazi Shahraki F, Zandi N, Pazoki B, Farzaei MH, Ghasemi M, Abdollahi M, Abdolghaffari AH. Lashgari NA, et al. Curr Pharm Biotechnol. 2024;25(13):1632-1650. doi: 10.2174/0113892010261502231102040149. Curr Pharm Biotechnol. 2024. PMID: 38258770 - Extracellular vesicles in the treatment and prevention of osteoarthritis: can horses help us translate this therapy to humans?
O'Brien TJ, Hollinshead F, Goodrich LR. O'Brien TJ, et al. Extracell Vesicles Circ Nucl Acids. 2023 Jun;4(2):151-169. doi: 10.20517/evcna.2023.11. Epub 2023 Apr 17. Extracell Vesicles Circ Nucl Acids. 2023. PMID: 37829144 Free PMC article. - Phyllanthus emblica (Amla) methanolic extract regulates multiple checkpoints in 15-lipoxygenase mediated inflammopathies: Computational simulation and in vitro evidence.
Sharif MA, Khan AM, Salekeen R, Rahman MH, Mahmud S, Bibi S, Biswas P, Nazmul Hasan M, Islam KMD, Rahman SMM, Islam ME, Alshammari A, Alharbi M, Hayee A. Sharif MA, et al. Saudi Pharm J. 2023 Aug;31(8):101681. doi: 10.1016/j.jsps.2023.06.014. Epub 2023 Jun 21. Saudi Pharm J. 2023. PMID: 37576860 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials